Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-Up
2018
Narcolepsytype 1 is a rare disabling sleep disorder mainly characterized by
excessive daytime sleepinessand
cataplexy, an emotion-triggered sudden loss of
muscle tone. Patients have a selective degeneration of hypocretin-producing neurons in the
dorsolateralposterior hypothalamus with growing evidence supporting the hypothesis of an autoimmune mechanism. Few case studies that reported intravenous immunoglobulin therapy (IVIg) suggest the efficacy of IVIg when administered early after disease onset, but the results are controversial. In these retrospective case observations, IVIg cycles were initiated within one to four months after
cataplexyonset in a twenty-seven-year-old man, a ten-year-old girl, and a seven-year-old boy, all three with early onset typical
narcolepsytype 1. Efficacy of treatment (three IVIg cycles of 1 g/kg administered at four-week intervals) was evaluated based on clinical, polysomnographic, and
multiple sleep latency test(mean latency and SOREM) follow-up. Two patients reported decreased
cataplexyfrequency and ameliorated daytime sleepiness, but no significant amelioration of polysomnographic parameters was observed. Given the possibility of spontaneous improvement of
cataplexyfrequency with self-behavioral adjustments, these observations would need to be confirmed by larger controlled studies. Based on the present study and current literature, proof of concept is still missing thus prohibiting the consideration of IVIg as an efficient treatment option.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
18
References
7
Citations
NaN
KQI